You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
VEBrant Study: Positive Findings of Vebreltinib for Advanced Clear Cell Sarcoma Presented at ASCO 2026
Author：Avistone
Time：2026-06-04
01 Abstract:
Presentation Type: Oral Abstract Session
Abstract Title: Efficacy and safety of Vebreltinib (PLB1001) in advanced clear cell sarcoma (VEBrant): a multicenter, phase II study
Local Presentation Time: 4:00–4:12 PM, May 30th
Venue: S100bc | Live Stream
Presenter: Binghao Li, The Second Affiliated Hospital of Zhejiang University School of Medicine
02 Key Information:
Clear cell sarcoma (CCS) is an ultra rare cancer with no established standard systemic therapy of proven efficacy. The c-MET pathway plays an important role in CCS, with MET overexpression frequently observed. Targeted therapy by type Ia MET inhibitor crizotinib revealed a disease control rate (DCR) at 69.2% and objective response rate (ORR) at 3.8%. Vebreltinib is a highly selective type Ib MET inhibitor with verified efficacy in solid tumor harboring MET alterations, such as NSCLC with MET amplification or overexpression. This phase II study aimed to assess the efficacy and safety of Vebreltinib for advanced CCS. Methods: Patients (pts) with histopathologically confirmed, unresectable or metastatic CCS were en rolled (NCT07153887), regardless of prior therapy except for any MET inhibitors. Eligible pts received Vebreltinib (200 mg BID) until disease progression, intolerable toxicity, or death occurs. Prior PD1/PDL1 treatment for at least 4 months without tumor reduction are allowed to continue using the same PD1/PDL1 medicine after thorough evaluation by the investigator. Evaluation of tumor response was performed every 2 months. Primary endpoints was ORR per RECIST v1.1. Secondary endpoints included DCR, PFS, OS, 12m-OSR, DoR and treatment safety. MET expression by immunohistochemistry was collected when possible. A Simon’s two-stage design was applied: if no responses were seen in the first 13 pts, the study would stop; otherwise, 14 additional pts would be enrolled (total N=27). Results: At data cutoff on January 23, 2026, 23 pts were enrolled. Median age was 29 years (range: 16–59), 47.8% were male, 91.3% had prior surgery, and 95.7% received prior systemic therapy. All had metastatic disease, primarily to lung (78.3%), lymph nodes (56.5%), and bone (30.4%). With median follow-up of 134 days and median treatment duration of 103 days, 17 pts were evaluable for response. ORR was 41.2% (7 partial responses) and DCR was 70.6% (7 PR, 5 stable disease), meeting the pre-specified threshold for stage I continuation. Median PFS was 4.14 months (95% CI: 2.3–NA); 6-month PFS rate was 42.8%. Median OS was not reached. Treatment-related adverse events (TRAEs) occurred in 87.0% of pts, mostly grade 1-2. Grade 3-4 TRAEs occurred in 21.7% (n=5; rash n=4, fever n=1). Notably, 4 pts discontinued due to grade 4 rash within 2 weeks of starting vebreltinib combined with immunotherapy. Conclusions: Vebreltinib demonstrated notable antitumor activity for advanced CCS, representing a marked improvement over existing therapeutic options. Attention should be paid to the risk of severe rash, particularly when combined with immunotherapy. Longer follow-up is required to further confirm the efficacy and safety.
Figure 1: Waterfall Plot of Anti-tumor Responses in CCS Patients
Figure 2: PFS Kaplan-Meier Survival Curve for CCS Study Population
Figure 3: OS Kaplan-Meier Survival Curve for CCS Study Population
Figure 4: Tumor Shrinkage in a Representative CCS Patient After 6 Months of Vebreltinib 200 mg BID plus PD-1 Combination Therapy
Patient’s Prior Treatment History: Prior anlotinib 12 mg plus PD-1 therapy with stable disease (SD, progressive tumor burden) as best overall response.
Reference：
1.Mavrogenis A, Bianchi G, Stavropoulos N, Papagelopoulos P, Ruggieri P. Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts. Hippokratia. 2013 Oct;17(4):298-302.
2.Cornillie J, et al. Biology and management of clear cell sarcoma: state of the art and future perspectives. Expert Rev Anticancer Ther, 2016, 16(8):839-845.
3.Schöffski P, Wozniak A, Kasper B, et al. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. Ann Oncol. 2018;29(3):758-765.
4.Yang J-J, et al. Vebreltinib for NSCLC with c-Met Exon 14 Skipping Mutation. J Clin Oncol 2024; 42(31): 3680-3691.
5. Wu YL, Yao Y, Yang JJ, et al. Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study [J]. Lancet Oncol, 2026, 27 (1): 36-44.
6. Zhou F, Ren SX, Che GW, et al. Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: A phase Ib/II study [J]. J Clin Oncol, 2025, 43 (15 Suppl): 8632.
Forward-Looking Statements;
The forward-looking statements made in this article relate only to events or information as of the date on which such statements are made in this article. Except as required by law, after the date of making the forward-looking statements, we shall have no obligation to update or publicly revise any forward-looking statements or unforeseen events, regardless of whether new information, future events or other circumstances arise. Please read this article carefully and understand that our actual future results or performance may differ materially from expectations. All statements contained in this article are made as of the publication date of this article and are subject to change in light of future developments.
